Skip to main content

Table 3 Categorisation 2: non-high FeNO and non-high blood eosinophils vs. non-high FeNO and high blood eosinophils

From: Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations

Characteristics Non-high FeNO and non-high blood eosinophils (n = 186) Non-high FeNO and high blood eosinophils (n = 186) p-value
Sex
 n (% non-missing) 186 (100.0) 186 (100.0) 1.0000
 Male 77 (41.4) 77 (41.4)  
Age
 n (% non-missing) 186 (100.0) 186 (100.0) 0.9834
 Mean (SD) 51.9 (13.1) 51.8 (13.7)  
 Median (IQR) 55.0 (20.0) 53.5 (20.0)  
Age group
 n (% non-missing) 186 (100.0) 186 (100.0) 0.1919
 Under 35 22 (11.8) 24 (12.9)  
 35–65 141 (75.8) 127 (68.3)  
 44–80 23 (12.4) 35 (18.8)  
Smoking status
 n (% non-missing) 186 (100.0) 186 (100.0) 1.0000
 Non-smoker 67 (36.0) 67 (36.0)  
 Ex-smoker 22 (11.8) 22 (11.8)  
 Current smoker 67 (36.0) 67 (36.0)  
BMI
 n (% non-missing) 184 (98.4) 184 (98.4) 0.0492
 Mean (SD) 30.1 (6.3) 29.0 (6.7)  
FeNO
 n (% non-missing) 186 (100.0) 186 (100.0) <0.0001
 Mean (SD) 16.5 (7.8) 28.9 (23.8)  
 Median (IQR) 16.0 (12.0) 23.0 (22.0)  
Blood eosinophil count
 n (% non-missing) 186 (100.0) 184 (98.9) <0.0001
 Mean (SD) 0.2 (0.1) 0.4 (0.2)  
 Median (IQR) 0.2 (0.1) 0.4 (0.2)  
Active eczema diagnosisa
 n (% non-missing) 186 (100.0) 186 (100.0) 0.1876
 Yes 5 (2.7) 10 (5.4)  
Active rhinitis diagnosisa
 n (% non-missing) 186 (100.0) 186 (100.0) 0.0720
 Yes 49 (26.3) 65 (34.9)  
Eczema diagnosis    
 n (% non-missing) 186 (100.0) 186 (100.0) 0.2273
 Yes 57 (30.6) 68 (36.6)  
Rhinitis diagnosis
 n (% non-missing) 186 (100.0) 186 (100.0) 0.0272
 Yes 67 (36.0) 88 (47.3)  
IHD diagnosis    
 n (% non-missing) 186 (100.0) 186 (100.0) 0.4564
 Yes 7 (3.8) 10 (5.4)  
Heart failure diagnosis
 n (% non-missing) 186 (100.0) 186 (100.0) 0.3167
 Yes 0 (0.0) 1 (0.5)  
Hypertension diagnosis
 n (% non-missing) 186 (100.0) 186 (100.0) 0.3212
 Yes 46 (24.7) 38 (20.4)  
Diabetes diagnosis    
 n (% non-missing) 186 (100.0) 186 (100.0) 0.5736
 Yes 14 (7.5) 17 (9.1)  
GERD active diagnosis
 N (% non-missing) 186 (100.0) 186 (100.0) 0.4352
 Yes 26 (14.0) 21 (11.3)  
Predicted peak flow    
 n (% non-missing) 98 (52.7) 101 (54.3) 0.8525
 Mean (SD) 515.7 (75.3) 517.3 (76.2)  
ICS/LABA prescriptions per patient
 n (% non-missing) 186 (100.0) 186 (100.0) 0.0404
 Mean (SD) 3.8 (3.9) 4.4 (3.8)  
 Median (IQR) 3.0 (6.0) 4.0 (5.0)  
Mono ICS prescriptions per patient
 n (% non-missing) 186 (100.0) 186 (100.0) 0.0362
 Mean (SD) 1.3 (2.5) 0.7 (1.6)  
 Median (IQR) 0.0 (1.0) 0.0 (1.0)  
Mean daily SABA dosage (µg)
 n (% non-missing) 186 (100.0) 186 (100.0) 0.2585
 <100 63 (33.9) 71 (38.2)  
 100–200 57 (30.6) 48 (25.8)  
 201–400 35 (18.8) 45 (24.2)  
 >400 31 (16.7) 22 (11.8)  
ICS adherenceb
 n (% non-missing) 186 (100.0) 186 (100.0) 0.8806
 Mean (SD) 69.2 (55.2) 66.2 (53.3)  
 Median (IQR) 54.8 (71.2) 56.1 (57.5)  
  1. All values in the table are n (%) unless otherwise specified. High FeNO defined as ≥ 35 ppb; non-high FeNO < 35 ppb; high blood eosinophil count defined as ≥ 0.300 × 109 cells/L; non-high blood eosinophil count < 0.300 × 109 cells/L
  2. BMI body mass index, FeNO fractional exhaled nitric oxide, GERD gastroesophageal reflux disease, ICS inhaled corticosteroid, IHD ischaemic heart disease, IQR interquartile range, LABA long-acting β2-agonist, ppb parts per billion, SABA short-acting β2-agonist, SD standard deviation
  3. aActive denotes diagnosed in the year before FeNO reading or treated in the year before FeNO reading
  4. bMedication Possession Ratio was calculated by dividing the total of 1 day’s supply by the total number of days evaluated, multiplied by 100%. The evaluation period for all patients was 365 days in the study year